Authors: Gestin, JF Loussouarn, A Bardies, M Gautherot, E Gruaz-Guyon, A Sai-Maurel, C Barbet, J Curtet, C Chatal, JF Faivre-Chauvet, A

Citation: Jf. Gestin et al., Two-step targeting of xenografted colon carcinoma using a bispecific antibody and Re-188-labeled bivalent hapten: Biodistribution and dosimetry studies, J NUCL MED, 42(1), 2001, pp. 146-153

Authors: Couturier, O Faivre-Chauvet, A Filippovich, IV Thedrez, P Sai-Maurel, C Bardies, M Mishra, AK Gauvrit, M Blain, G Apostolidis, C Molinet, R Abbe, JC Bataille, R Wijdenes, J Chatal, JF Cherel, M

Citation: O. Couturier et al., Validation of Bi-213-alpha radioimmunotherapy for multiple myeloma, CLIN CANC R, 5(10), 1999, pp. 3165S-3170S

Authors: Gautherot, E Kraeber-Bodere, F Daniel, L Fiche, M Rouvier, E Sai-Maurel, C Thedrez, P Chatal, JF Barbet, J

Citation: E. Gautherot et al., Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with I-131-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody, CLIN CANC R, 5(10), 1999, pp. 3177S-3182S

Authors: Kraeber-Bodere, F Faivre-Chauvet, A Sai-Maurel, C Campion, L Fiche, M Gautherot, E Le Boterff, J Barbet, J Chatal, JF Thedrez, P

Citation: F. Kraeber-bodere et al., Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: Comparison of iodine 131-labeled F(ab ')(2) and pretargeted bivalent hapten and evaluation of repeated injections, CLIN CANC R, 5(10), 1999, pp. 3183S-3189S

Authors: Kraeber-Bodere, F Faivre-Chauvet, A Sai-Maurel, C Gautherot, E Fiche, M Campion, L Le Boterff, J Barbet, J Chatal, JF Thedrez, P

Citation: F. Kraeber-bodere et al., Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J NUCL MED, 40(1), 1999, pp. 198-204